ClinicalTrials.gg
CompletedNCT04470167Updated May 18, 2023

Phase 1/2 Clinical Study of TPX-115 in Patients With Partial-Thickness Rotator Cuff Tear

A Phase 1/2 interventional study of TPX-115 and Placebo in Rotator Cuff Injuries, sponsored by Tego Science, Inc.. Completed at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by Tego Science, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of — 3 open to participants now, 4 under way, 1 of them phase 3. Rotator Cuff Injuries · Korea, Republic of.

Enrollment
18th of 25
49 · median 74
Started
2020
with 3 others
Phase 1/2
Only one
of the 30
Registered
16th of 30
by date
Lead sponsor
3 of 30
Tego Science, Inc.

Among the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, this one is the 18th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2020, is the only one in phase 1/2, and was the 16th registered.

Rotator Cuff Injuries

631 studies on the registry are indexed under Rotator Cuff Injuries; 156 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

3 of the 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Rotator Cuff Injuries with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Rotator cuff tear is one of the most common shoulder diseases and conservative treatment is commonly used for tears involving ≤50% of tendon thickness. Since conventional conservative treatments are not fundamental to repair tendon tissue, there is a growing need of new therapy to improve structural outcome. This study assesses the safety and efficacy of allogeneic fibroblasts on partial-thickness rotator cuff tear. The primary outcome is change in American Shoulder and Elbow Surgeons (ASES) score at 24 weeks after TPX-115 injection. Secondary outcomes include changes from baseline in Visual Analogue Score (VAS) pain score, functional evaluations including Range of Motion (ROM), Constant Score (CS), ASES score and Simple Shoulder Test (SST) at 4, 12 and 24 weeks after administration and structural evaluation using MRI at 24 weeks after injection.

03

Conditions studied

  • Rotator Cuff Injuries

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must;

  1. Be 19 years of age or older.
  2. Have partial-thickness rotator cuff tear, ≤50% of tendon thickness or of Ellman grade I, II assessed by MRI.
  3. Have unilateral shoulder pain lasting more than 3 months despite conservative treatment and VAS pain score ≥5 at screening.
  4. Understand fully the study and voluntarily sign the for participation in the study.

Exclusion criteria

Exclusion Criteria:

Participants with any of the following conditions will be excluded unless stated otherwise;

  1. Have partial-thickness rotator cuff tear larger than 50% of tendon thickness or of Ellman grade III, or full-thickness rotator cuff tear confirmed by MRI.
  2. Have prior medical history of shoulder surgery on the torn rotator cuff or the upper part of shoulder within 6 months prior to screening visit (shoulder trauma, fracture, upper cervical spine surgery, etc.).
  3. Have had subacromial or intra-articular injections on the affected shoulder within 3 months prior to screening visit.
  4. Have had received systemic or agents within 4 weeks prior to screening visit.
  5. Have been diagnosed with the following diseases.

    • Inflammatory joint diseases
    • Other shoulder diseases which may cause shoulder pain or functional disorder
    • diseases
    • Active or C
    • Ab positive
    • Malignant tumors within the last 5 years
    • Coagulopathy
    • Genetic disorders related to fibroblasts of collagen
    • Other serious diseases deemed to affect the results of the study
  6. Have allergies to bovine proteins or gentamicin.
  7. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of suggested in this study.
  8. Have participated in other clinical trials and received agents within 4 weeks of this study
  9. Be deemed inadequate for the study by investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    TPX-115

    Subjects receive ultrasound-guided intratendinous injection of TPX-115

    Biological: TPX-115

  • Placebo comparator
    Placebo

    Subjects receive ultrasound-guided intratendinous placebo injection

    Other: Placebo

Interventions

  • BiologicalTPX-115

    Ultrasound-guided intratendinous injection of allogeneic fibroblasts(TPX-115)

  • OtherPlacebo

    Ultrasound-guided intratendinous placebo injection

06

What researchers measure

Primary outcomes

  1. Change in shoulder score of American Shoulder and Elbow Surgeons (ASES)

    ASES shoulder score is derived from the Visual Analogue Scale (VAS) score for pain and activities of daily living score. The total score - maximum of 100 points - is weighted 50% for pain and 50% for function.

    Time frame: 24 weeks

Secondary outcomes

  1. Change in shoulder score of American Shoulder and Elbow Surgeons (ASES)

    ASES shoulder score is derived from the Visual Analogue Scale (VAS) score for pain and the activities of daily living score. The total score - maximum of points - is weighted 50% for pain and 50% for function.

    Time frame: 4, 12 weeks

  2. Change in pain score of Visual Analogue Scale (VAS)

    VAS pain score is measured on a scale of 0 (no pain) to 10 (worst pain imaginable).

    Time frame: 4, 12, 24 weeks

  3. Change in Range of Motion (ROM)

    Measurement of ROM for forward elevation, external rotation at 90º abduction, external rotation at side and internal rotation at back.

    Time frame: 4, 12, 24 weeks

  4. Change in Constant score (CS)

    The CS total score (100) = Pain (15) + Activity of Daily Living (20) + Mobility (40) + Strength(25)

    Time frame: 4, 12, 24 weeks

  5. Change in Simple Shoulder Test (SST) Score

    SST assesses functional disability of the shoulder (function related to pain, function/strength and Range of Motion).

    Time frame: 4, 12, 24 weeks

  6. Change in tear size on Magnetic Resonance Image (MRI)

    Tear size is assessed by an independent evaluator.

    Time frame: 24 weeks

  7. Change in tendon thickness on Magnetic Resonance Image (MRI)

    Tendon thickness is assessed by an independent evaluator.

    Time frame: 24 weeks

  8. Change in tear/footprint on MRI

    Ratio of tear lengths to whole footprint length is measured by an independent evaluator.

    Time frame: 24 weeks

  9. Change of tendinosis on MRI

    Tendinosis is assessed with tendinosis grading system by an independent evaluator. (0: normal, 1: mild, 2: moderate, 3: marked)

    Time frame: 24 weeks

07

Study locations

2 sites
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Feb 2022, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2020
First posted
Jul 14, 2020
StartActual
Oct 26, 2020
Primary completionActual
Feb 17, 2022
CompletionActual
Feb 17, 2022
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04470167
Lead sponsor
Tego Science, Inc.
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Oct 26, 2020
Primary completion
Feb 17, 2022
Completion
Feb 17, 2022
Last update
May 18, 2023

Study contacts

Joo Han Oh, Ph.D
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TPX-115

Start the discussion